AZ's Lynparza Gets Prostate Cancer Priority Review

Hot On The Heels Of Clovis PARP Inhibitor Rubraca

 
• By Kevin Grogan

The race is firmly on to be the first PARP inhibitor approved for metastatic castration-resistant prostate cancer, with the FDA giving a speedy review to AstraZeneca and Merck & Co's Lynparza just days after granting the same to Clovis Oncology's Rubraca.

Horse racing
AZ and Clovis neck and neck in prostate cancer • Source: Shutterstock

More from New Products

More from Scrip